BACKGROUND: Recurrent high-grade gliomas in adults remain a deadly cancer with median survival of less than 1 year. In the absence of effective agents, immunotherapy with checkpoint inhibitors has been adopted as a potentially beneficial next step for recurrences with hypermutated or mismatch repair-mutated phenotypes. The rationale for their use, however, is based on case reports and studies with other types of cancer. METHODS: We reviewed 4 cases of hypermutated or mismatch repair-mutated recurrent high-grade gliomas treated with checkpoint inhibitors. RESULTS: All cases had recurrent high-grade glioma that harbored either a hypermutated phenotype and/or a mismatch repair mutation. Treatment with checkpoint inhibitor therapy resulted in no significant response. CONCLUSIONS: In our experience, hypermutated or mismatch repair-mutated high-grade gliomas in adults do not respond to checkpoint inhibitors alone. This lack of efficacy is in agreement with underwhelming results of clinical trials examining checkpoint inhibitors in high-grade gliomas. The case reports of responders have been in pediatric patients with glioma and are likely a different subtype altogether.
BACKGROUND: Recurrent high-grade gliomas in adults remain a deadly cancer with median survival of less than 1 year. In the absence of effective agents, immunotherapy with checkpoint inhibitors has been adopted as a potentially beneficial next step for recurrences with hypermutated or mismatch repair-mutated phenotypes. The rationale for their use, however, is based on case reports and studies with other types of cancer. METHODS: We reviewed 4 cases of hypermutated or mismatch repair-mutated recurrent high-grade gliomas treated with checkpoint inhibitors. RESULTS: All cases had recurrent high-grade glioma that harbored either a hypermutated phenotype and/or a mismatch repair mutation. Treatment with checkpoint inhibitor therapy resulted in no significant response. CONCLUSIONS: In our experience, hypermutated or mismatch repair-mutated high-grade gliomas in adults do not respond to checkpoint inhibitors alone. This lack of efficacy is in agreement with underwhelming results of clinical trials examining checkpoint inhibitors in high-grade gliomas. The case reports of responders have been in pediatric patients with glioma and are likely a different subtype altogether.
Authors: Daniel P Cahill; Kymberly K Levine; Rebecca A Betensky; Patrick J Codd; Candice A Romany; Linsey B Reavie; Tracy T Batchelor; P Andrew Futreal; Michael R Stratton; William T Curry; A John Iafrate; David N Louis Journal: Clin Cancer Res Date: 2007-04-01 Impact factor: 12.531
Authors: E Zeynep Erson-Omay; Ahmet Okay Çağlayan; Nikolaus Schultz; Nils Weinhold; S Bülent Omay; Koray Özduman; Yavuz Köksal; Jie Li; Akdes Serin Harmancı; Victoria Clark; Geneive Carrión-Grant; Jacob Baranoski; Caner Çağlar; Tanyeri Barak; Süleyman Coşkun; Burçin Baran; Doğan Köse; Jia Sun; Mehmet Bakırcıoğlu; Jennifer Moliterno Günel; M Necmettin Pamir; Ketu Mishra-Gorur; Kaya Bilguvar; Katsuhito Yasuno; Alexander Vortmeyer; Anita J Huttner; Chris Sander; Murat Günel Journal: Neuro Oncol Date: 2015-03-03 Impact factor: 12.300
Authors: Thierry Gorlia; Roger Stupp; Alba A Brandes; Roy R Rampling; Pierre Fumoleau; Christian Dittrich; Mario M Campone; Chris C Twelves; Eric Raymond; Monika E Hegi; Denis Lacombe; Martin J van den Bent Journal: Eur J Cancer Date: 2012-03-28 Impact factor: 9.162
Authors: Chris Hunter; Raffaella Smith; Daniel P Cahill; Philip Stephens; Claire Stevens; Jon Teague; Chris Greenman; Sarah Edkins; Graham Bignell; Helen Davies; Sarah O'Meara; Adrian Parker; Tim Avis; Syd Barthorpe; Lisa Brackenbury; Gemma Buck; Adam Butler; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Matthew Gorton; Kristian Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jonathon Hinton; Andy Jenkinson; David Jones; Vivienne Kosmidou; Ross Laman; Richard Lugg; Andrew Menzies; Janet Perry; Robert Petty; Keiran Raine; David Richardson; Rebecca Shepherd; Alexandra Small; Helen Solomon; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andy Yates; Douglas F Easton; Gregory Riggins; Jennifer E Roy; Kymberly K Levine; Wolf Mueller; Tracy T Batchelor; David N Louis; Michael R Stratton; P Andrew Futreal; Richard Wooster Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701
Authors: Serah Choi; Yao Yu; Matthew R Grimmer; Michael Wahl; Susan M Chang; Joseph F Costello Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300
Authors: Hideho Okada; Michael Weller; Raymond Huang; Gaetano Finocchiaro; Mark R Gilbert; Wolfgang Wick; Benjamin M Ellingson; Naoya Hashimoto; Ian F Pollack; Alba A Brandes; Enrico Franceschi; Christel Herold-Mende; Lakshmi Nayak; Ashok Panigrahy; Whitney B Pope; Robert Prins; John H Sampson; Patrick Y Wen; David A Reardon Journal: Lancet Oncol Date: 2015-11 Impact factor: 41.316
Authors: Eric Bouffet; Valérie Larouche; Brittany B Campbell; Daniele Merico; Richard de Borja; Melyssa Aronson; Carol Durno; Joerg Krueger; Vanja Cabric; Vijay Ramaswamy; Nataliya Zhukova; Gary Mason; Roula Farah; Samina Afzal; Michal Yalon; Gideon Rechavi; Vanan Magimairajan; Michael F Walsh; Shlomi Constantini; Rina Dvir; Ronit Elhasid; Alyssa Reddy; Michael Osborn; Michael Sullivan; Jordan Hansford; Andrew Dodgshun; Nancy Klauber-Demore; Lindsay Peterson; Sunil Patel; Scott Lindhorst; Jeffrey Atkinson; Zane Cohen; Rachel Laframboise; Peter Dirks; Michael Taylor; David Malkin; Steffen Albrecht; Roy W R Dudley; Nada Jabado; Cynthia E Hawkins; Adam Shlien; Uri Tabori Journal: J Clin Oncol Date: 2016-03-21 Impact factor: 44.544
Authors: Tiffany R Hodges; Martina Ott; Joanne Xiu; Zoran Gatalica; Jeff Swensen; Shouhao Zhou; Jason T Huse; John de Groot; Shulin Li; Willem W Overwijk; David Spetzler; Amy B Heimberger Journal: Neuro Oncol Date: 2017-08-01 Impact factor: 12.300
Authors: Santiago Cabezas-Camarero; Rebeca Pérez-Alfayate; Vanesa García-Barberán; María Carmen Polidura; María Natividad Gómez-Ruiz; Isabel Casado-Fariñas; Issa Ahmad Subhi-Issa; José Carlos Plaza Hernández; Pilar Garre; Isabel Díaz-Millán; Pedro Pérez-Segura Journal: Ther Adv Med Oncol Date: 2022-06-08 Impact factor: 5.485
Authors: Víctor A Arrieta; Andrew X Chen; J Robert Kane; Seong Jae Kang; Cynthia Kassab; Crismita Dmello; Junfei Zhao; Kirsten B Burdett; Pavan S Upadhyayula; Catalina Lee-Chang; Joseph Shilati; Dinesh Jaishankar; Li Chen; Andrew Gould; Daniel Zhang; Jinzhou Yuan; Wenting Zhao; Xiaoyang Ling; Jared K Burks; Brice Laffleur; Christina Amidei; Jeffrey N Bruce; Rimas V Lukas; Jonathan T Yamaguchi; David Cieremans; Gerson Rothschild; Uttiya Basu; Matthew McCord; Daniel J Brat; Hui Zhang; Lee A D Cooper; Bin Zhang; Peter Sims; Tim F Cloughesy; Robert Prins; Peter Canoll; Roger Stupp; Amy B Heimberger; Craig Horbinski; Fabio M Iwamoto; Raul Rabadan; Adam M Sonabend Journal: Nat Cancer Date: 2021-11-29
Authors: Fan Yang; Zhenqiang He; Hao Duan; Duo Zhang; Juehui Li; Huijuan Yang; Jay F Dorsey; Wei Zou; S Ali Nabavizadeh; Stephen J Bagley; Kalil Abdullah; Steven Brem; Lin Zhang; Xiaowei Xu; Katelyn T Byrne; Robert H Vonderheide; Yanqing Gong; Yi Fan Journal: Nat Commun Date: 2021-06-08 Impact factor: 14.919